| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 02/27/2002 | CN1079674C Flavanolignan preparation, its processing method and pharmaceutical compositions containing them |
| 02/27/2002 | CN1079672C Oral liquid alendronate formulations |
| 02/27/2002 | CN1079670C Sublingual or buccal pharmaceutical composition |
| 02/27/2002 | CN1079669C Anti-acne composition |
| 02/27/2002 | CN1079668C Injectable liposumal pharmaceutical preparation |
| 02/27/2002 | CN1079665C Personal cleansing compositions |
| 02/27/2002 | CN1079642C Novel embolizing compositions |
| 02/26/2002 | US6350853 Conjugated peptide nucleic acids having enhanced cellular uptake |
| 02/26/2002 | US6350812 Hydrogels containing triblock copolymers, and preparation and use thereof |
| 02/26/2002 | US6350786 Complexes significantly increase the bioavailability of poorly soluble therapeutically active compounds |
| 02/26/2002 | US6350780 Methods and compositions for drug delivery |
| 02/26/2002 | US6350739 Methods of prevention and treatment of ischemic damage |
| 02/26/2002 | US6350594 A method using cultured plant cell gums produced from gum-secreting cells of vascular plants in a variety of food, drugs, veterinary, cosmetics and industry |
| 02/26/2002 | US6350470 Effervescent drug delivery system for oral administration |
| 02/26/2002 | US6350469 Tablet comprising compacted mixture of methylcellulose having high viscosity and edible calcium salt selected from dibasic calcium phosphate dihydrate, calcium phosphate anhydrous, and tribasic calcium phosphate, or mixtures thereof |
| 02/26/2002 | US6350468 Double capsule for the administration of active principles in multiple therapies |
| 02/26/2002 | US6350467 Pharmaceutical preparations of glutathione and methods of administration thereof |
| 02/26/2002 | US6350464 Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same |
| 02/26/2002 | US6350442 Ocular treatment using cyclosporin-A derivatives |
| 02/26/2002 | US6350437 Tooth pastes |
| 02/26/2002 | US6350432 Pressurized containers with propellants and glycerin derivatives |
| 02/26/2002 | CA2329474C Continuous low-dose cytokine infusion therapy |
| 02/26/2002 | CA2237883C Process for the preparation of materials with a high content of long chain polyunsaturated fatty acids |
| 02/26/2002 | CA2025728C Antimicrobial compositions |
| 02/26/2002 | CA2006717C Antibacterial anti-plaque oral composition mouthwash or liquid dentifrice |
| 02/21/2002 | WO2002014448A2 Adhesive blends comprising hydrophilic and hydrophobic pressure sensitive adhesives |
| 02/21/2002 | WO2002014361A2 NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 83P2H3 AND CaTrF2E11 USEFUL IN TREATMENT AND DETECTION OF CANCER |
| 02/21/2002 | WO2002014360A1 Integrin binding motif containing peptides and methods of treating skeletal diseases |
| 02/21/2002 | WO2002014288A1 Use of triazinetrione sulfones for combating coccidiosis |
| 02/21/2002 | WO2002014279A1 New aporphine esters and their use in therapy |
| 02/21/2002 | WO2002014251A1 Method for obtaining cocoa bean polyphenol extracts, resulting extracts and uses thereof |
| 02/21/2002 | WO2002013882A1 Implants with a phosphazene-containing coating |
| 02/21/2002 | WO2002013873A2 P97-active agent conjugates and their methods of use |
| 02/21/2002 | WO2002013872A1 Peptide and peptide mimetic conjugates with integrin-inhibitor properties |
| 02/21/2002 | WO2002013870A2 Formulation for administering therapeutic lipophilic molecules |
| 02/21/2002 | WO2002013869A2 Flavone-containing plant extract solutions having improved storage and heat stability |
| 02/21/2002 | WO2002013868A1 Dermatological formulation |
| 02/21/2002 | WO2002013862A2 Method and composition for altering a b cell mediated pathology |
| 02/21/2002 | WO2002013860A1 Stabilized antibody-containing preparations |
| 02/21/2002 | WO2002013859A1 Method of inhibiting antibody-containing solution from coagulating or becoming turbid |
| 02/21/2002 | WO2002013858A1 Oral solid dose vaccine |
| 02/21/2002 | WO2002013856A2 W/o emulsion adjuvant compositions for vaccines |
| 02/21/2002 | WO2002013843A2 Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours |
| 02/21/2002 | WO2002013817A1 Remedies for cisplatin-tolerant cancer |
| 02/21/2002 | WO2002013816A1 Pharmaceutical composition |
| 02/21/2002 | WO2002013815A1 Oral drug composition containing a verapamil derivative as a drug-absorption promotor |
| 02/21/2002 | WO2002013792A1 Drug-containing solid dispersion having improved solubility |
| 02/21/2002 | WO2002013791A2 Steroid hormones as transfer agents |
| 02/21/2002 | WO2002013790A1 Solid dispersion of ipriflavone for oral administration and its manufacturing methods |
| 02/21/2002 | WO2002013787A1 Composite material and process for increasing bioavailability and activity of a beneficial agent |
| 02/21/2002 | WO2002013782A1 Oral delivery of peptide |
| 02/21/2002 | WO2002013762A2 Improved solid pharmaceutical dosage formulation of hydrophobic drugs |
| 02/21/2002 | WO2002013701A1 Sutures and coatings made from therapeutic absorbable glass |
| 02/21/2002 | WO2001089482A3 Method for preparing microparticles having a selected polymer molecular weight |
| 02/21/2002 | WO2001083698A3 Compositions and methods for inducing activation of dendritic cells |
| 02/21/2002 | WO2001082894A3 Directly compressed solid dosage particles |
| 02/21/2002 | WO2001082873A3 A medicinal aerosol formulation |
| 02/21/2002 | WO2001082863A3 Polyacid/polyalkylene oxide foams and gels and methods for their delivery |
| 02/21/2002 | WO2001080837A3 Transdermal or transmucosal dosage forms with a nicotine-containing active substance combination for smoker disintoxication |
| 02/21/2002 | WO2001080619A3 Pharmaceutical composition containing citalopram |
| 02/21/2002 | WO2001079443A3 Albumin fusion proteins |
| 02/21/2002 | WO2001076601A3 Pharmaceutical compositions comprising salmeterol and ipratropium |
| 02/21/2002 | WO2001076561A3 Pharmaceutical compositions |
| 02/21/2002 | WO2001076554A3 Drug delivery composition and device |
| 02/21/2002 | WO2001074314A3 Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| 02/21/2002 | WO2001074313A3 Compositions and methods for treating hair loss using c16 - c20 aromatic tetrahydro prostaglandins |
| 02/21/2002 | WO2001066089A3 Pharmaceutical compositions comprising cannabis |
| 02/21/2002 | WO2001062827A3 N-maleimidyl polymer derivatives |
| 02/21/2002 | WO2001059110A3 34p3d7: a tissue specific protein highly expressed in prostate cancer |
| 02/21/2002 | WO2001058910A3 Lipid-based drug delivery systems |
| 02/21/2002 | WO2001057069A3 Targeting peptides |
| 02/21/2002 | WO2001055391A3 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer |
| 02/21/2002 | WO2001052817A3 Cochleate formulations and their use for delivering biologically relevant molecules |
| 02/21/2002 | WO2001051008A3 Selective activation of a th1 or th2 lymphocyte regulated immune response |
| 02/21/2002 | WO2001045671A3 Suspension comprising oxcarbazepine |
| 02/21/2002 | WO2001043775A3 Hydroxide-releasing agents as skin permeation enhancers |
| 02/21/2002 | WO2001041912A3 Ether-capped poly(oxyalkylated) alcohol surfactants |
| 02/21/2002 | WO2001037812A3 Gastroretentive controlled release pharmaceutical dosage forms |
| 02/21/2002 | WO2001036004A3 Use of egf genistein for treatment egf-receptor expressing cancers |
| 02/21/2002 | WO2001030323A3 Controlled-release biocompatible ocular drug delivery implant devices and methods |
| 02/21/2002 | WO2001028516A3 Sustained-release formulations for treating cns-mediated disorders |
| 02/21/2002 | WO2001003649A3 Compositions and methods for the treatment of parkinson's disease |
| 02/21/2002 | WO2000078355A3 Biologically active materials |
| 02/21/2002 | US20020022781 Products and methods for brachytherapy |
| 02/21/2002 | US20020022738 Solubility makes it possible to manufacture a solution of higher concentration of the compound and high-dosage drug product |
| 02/21/2002 | US20020022667 For inducing or maintaining anesthesia or sedation in a patient |
| 02/21/2002 | US20020022664 For therapy of sub-dermal plaque or scar tissue formation or accumulations, such as Peyronie's disease, Dupuytren's contracture, Ledderhose Fibrosis, scars, hemangiomas, and lipoederma ("cellulite") |
| 02/21/2002 | US20020022660 For disinfecting surfaces, long-lasting antimicrobial activity |
| 02/21/2002 | US20020022658 Methods for selectively occluding blood supplies to neoplasias |
| 02/21/2002 | US20020022610 Compositions and methods for treating bacterial infections |
| 02/21/2002 | US20020022603 Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced GI toxicity |
| 02/21/2002 | US20020022590 Useful as antibiotics; reduced tissue accumulation and/or nephrotoxicity when administered to a mammal; useful against vancomycin-resistant microorganisms |
| 02/21/2002 | US20020022266 Coupling compound to tissue |
| 02/21/2002 | US20020022052 Transdermal delivery system |
| 02/21/2002 | US20020022042 Containing wicking fibers |
| 02/21/2002 | US20020022038 Polymeric and, or wax envelopes |
| 02/21/2002 | US20020022034 Therapeutic DNA vaccination |
| 02/21/2002 | US20020022027 Complexing to polypeptides; antiproliferation agent |
| 02/21/2002 | US20020022012 Stability, nontoxic; anthrax |
| 02/21/2002 | US20020022005 Compositions for treating cystic fibrosis |